Showing 1 - 10 of 14
Persistent link: https://www.econbiz.de/10011760530
Persistent link: https://www.econbiz.de/10011760640
Ex-ante regulations and ex-post liabilities for using a new technology will induce additional costs for adopters. The standard model is advanced by including irreversibility and uncertainty and taking into account transaction costs of negotiating possible cost reductions. The case analysed is...
Persistent link: https://www.econbiz.de/10003905106
Ex-ante regulations and ex-post liabilities for using a new technology will induce additional costs for adopters. The standard model is advanced by including irreversibility and uncertainty and taking into account transaction costs of negotiating possible cost reductions. The case analysed is...
Persistent link: https://www.econbiz.de/10003935226
Persistent link: https://www.econbiz.de/10009260857
Persistent link: https://www.econbiz.de/10009262047
Persistent link: https://www.econbiz.de/10003302785
Persistent link: https://www.econbiz.de/10003429394
Persistent link: https://www.econbiz.de/10014470798
Pricing of biotechnology innovation under a patent grant is reconsidered in a model with uncertain returns and irreversible costs and benefits. Past results on restricted monopoly pricing in the presence of competing technologies showed that pricing power is reduced. The timing of adoption of an...
Persistent link: https://www.econbiz.de/10012911020